STOCK TITAN

Veradermics, Incorporated (MANE) 10-K Filings

MANE NYSE

Here are the 10-K annual reports from Veradermics, Incorporated (MANE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow MANE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MANE filings page.

Rhea-AI Summary

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on treating pattern hair loss (PHL) in men and women. Its lead candidate, VDPHL01, is an extended‑release oral form of minoxidil designed to boost hair growth while limiting cardiac side effects.

The company is running three registration-directed, placebo-controlled trials: two in male PHL patients using an 8.5 mg dose and one in female patients using a 4.5 mg dose, with all male trials fully enrolled. Early Phase 2 data in men showed faster, more consistent and denser hair regrowth versus historical topical and immediate‑release oral minoxidil, with 90.5% of patients reporting improved hair coverage at four months and generally good tolerability.

Veradermics estimates the current U.S. PHL treatment market at about $9 billion annually and plans a cash-pay, multi‑channel commercial strategy centered on dermatologists, direct‑to‑consumer advertising, social media and telehealth. The company intends to seek U.S. approval for VDPHL01 through the 505(b)(2) pathway and holds patents expected to extend into at least 2043, but highlights substantial ongoing losses, dependence on VDPHL01’s success, the need for additional financing, competitive pressures and significant clinical, regulatory and commercialization risks.